Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus

Vaccine. 2010 Jul 12;28(31):5023-30. doi: 10.1016/j.vaccine.2010.05.014. Epub 2010 May 21.


Serum bactericidal activity using human complement is the basis for established correlates of protection against invasive meningococcal disease. During the development of multicomponent protein-based vaccines against meningococcus B, it is necessary to measure antigen-specific bactericidal responses. This is not straightforward because each strain may be killed by antibodies to multiple antigens. We characterized a large panel of strains and, using a competitive inhibition SBA, we identified four strains that are each specifically killed by bactericidal antibodies to one of the major vaccine components. These strains provide a straightforward approach to demonstrate protective responses to each component of the vaccine and demonstrate that each of the antigens in the vaccine is sufficient to provide a potentially protective level of bactericidal activity.

MeSH terms

  • Animals
  • Antibodies, Bacterial / immunology*
  • Blood Bactericidal Activity
  • Complement System Proteins / immunology
  • Female
  • Humans
  • Meningococcal Infections / immunology*
  • Meningococcal Infections / prevention & control
  • Meningococcal Vaccines / immunology*
  • Mice
  • Neisseria meningitidis, Serogroup B / classification
  • Neisseria meningitidis, Serogroup B / immunology*
  • Vaccines, Synthetic / immunology


  • Antibodies, Bacterial
  • Meningococcal Vaccines
  • Vaccines, Synthetic
  • Complement System Proteins